NEW YORK (GenomeWeb) – European sample prep firm Novacyt has announced it will validate its Novaprep liquid-based cytology platform with an assay for high-risk human papillomavirus from Abbott.

Abbott and Novacyt will collaborate to systematically validate Novaprep's performance compared to storage vials used by competing liquid-based cytology systems for Abbott's RealTime High Risk HPV assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.